For research use only. Not for therapeutic Use.
Oxaliplatin（Cat No.:I013949）is a platinum-based chemotherapeutic agent used primarily in the treatment of colorectal cancer. It works by forming cross-links with DNA, inhibiting DNA replication and transcription, which leads to cell cycle arrest and apoptosis in rapidly dividing cancer cells. Oxaliplatin is often combined with other drugs, such as 5-fluorouracil (5-FU) and leucovorin, in regimens like FOLFOX, enhancing its effectiveness. Known for its efficacy in metastatic and advanced-stage cancers, oxaliplatin plays a critical role in cancer treatment, despite its side effects, including peripheral neuropathy.
| Catalog Number | I013949 |
| CAS Number | 61825-94-3 |
| Molecular Formula | C₈H₁₄N₂O₄Pt |
| Purity | ≥95% |
| Target | AutophagyDNA Alkylator/Crosslinker |
| Solubility | DMF: 17.5 mg/mL(Need ultrasonic and warming); H2O: 1.7 mg/mL (Need ultrasonic and warming) |
| IUPAC Name | [(1R,2R)-2-azanidylcyclohexyl]azanide;oxalic acid;platinum(2+) |
| InChI | InChI=1S/C6H12N2.C2H2O4.Pt/c7-5-3-1-2-4-6(5)8;3-1(4)2(5)6;/h5-8H,1-4H2;(H,3,4)(H,5,6);/q-2;;+2/t5-,6-;;/m1../s1 |
| InChIKey | DRMCATBEKSVAPL-BNTLRKBRSA-N |
| SMILES | C1CC[C@H]([C@@H](C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2] |
| Reference | [1]. Raymond E, et al. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol. 1998 Oct;9(10):1053-71.<br>[2]. Mohammed MQ, et al. Oxaliplatin is active in vitro against human melanoma cell lines: comparison with cisplatin and carboplatin. Anticancer Drugs. 2000 Nov;11(10):859-63.<br>[3]. Pendyala L, et al. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res. 1993 Dec 15;53(24):5970-6.<br>[4]. Wang Z, et al. Oxaliplatin induces apoptosis in hepatocellular carcinoma cells and inhibits tumor growth. Expert Opin Investig Drugs. 2009 Nov;18(11):1595-604<br>[5]. Mathé G, et al. Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum. Biomed Pharmacother. 1989;43(4):237-50.<br>[6]. Schellingerhout D, et al. Impairment of retrograde neuronal transport in oxaliplatin-induced neuropathy demonstrated by molecular imaging. PLoS One. 2012;7(9):e45776. doi: 10.1371/journal.pone.0045776. Epub 2012 Sep 20.<br>[7]. Romero HK, et al. Inhibition of α9α10 nicotinic acetylcholine receptors prevents chemotherapy-induced neuropathic pain. Proc Natl Acad Sci U S A. 2017 Mar 7;114(10):E1825-E1832. |
